Cerus Corporation to Release Second Quarter 2022 Financial Results on August 4, 2022

Rhea-AI Summary

Cerus Corporation (CERS) will release its second quarter 2022 financial results on August 4, 2022, post-market. A conference call is scheduled for 4:30 PM ET to discuss the results and business outlook. The company focuses on safeguarding the global blood supply, with its INTERCEPT Blood System approved for platelets and plasma. The red blood cell system is undergoing regulatory review in Europe and clinical development in the US. A replay of the call will be available on the company's website.

Positive

• INTERCEPT Blood System is the only pathogen reduction system with both CE mark and FDA approval for platelets and plasma.
• INTERCEPT red blood cell system is in late-stage clinical development in the US and under regulatory review in Europe.

Negative

• None.

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2022 financial results will be released on Thursday, August 4, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event.

A replay will be available on Cerus’ website and will be available approximately three hours after the call through August 18, 2022.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005002/en/

Matt Notarianni – Senior Director, Investor Relations

Cerus Corporation

925-288-6137

Source: Cerus Corporation

FAQ

When will the second quarter 2022 results for Cerus Corporation be released?

Cerus Corporation will release its second quarter 2022 financial results on August 4, 2022.

What time is the Cerus Corporation conference call scheduled for?

The conference call for Cerus Corporation is scheduled for 4:30 PM ET on August 4, 2022.

What is the focus of Cerus Corporation?

Cerus Corporation is dedicated to safeguarding the global blood supply with its pathogen-reduction technologies.

What products does Cerus Corporation offer?

Cerus Corporation offers the INTERCEPT Blood System for pathogen protection in platelets, plasma, and red blood cells.

Is the INTERCEPT Blood System approved by regulatory agencies?

Yes, the INTERCEPT Blood System for platelets and plasma has CE mark and FDA approval.